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Abstract
Background: T helper 17 (Th17) cells can recruit neutrophils to inflammatory sites through production of IL-17,
which induces chemokine release. IL-23 is an important inducer of IL-17 and IL-22 production. Our aim was to
study the role of Th17 cells in cystic fibrosis (CF) lung disease by measuring IL-17 protein and mRNA levels and
IL-22 and IL-23 mRNA in sputum of clinically stable CF patients and by comparing these levels with healthy
controls.
Methods: Sputum induction was performed in adult CF patients outside of an exacerbation and healthy control
subjects. IL-17A protein levels were measured in supernatants with cytometric bead array (CBA) and RNA was
isolated and quantitative RT-PCR was performed for IL-17A, IL-22 and IL-23.
Results: We found significantly higher levels of IL-17A protein and mRNA levels (both: p < 0.0001) and IL-23 mRNA
levels (p < 0.0001) in the sputum of CF group as compared to controls. We found very low levels of IL-22 mRNA in
the CF group. The levels of IL-17 and IL-23 mRNA were higher in patients chronically infected with Pseudomonas
aeruginosa (P. aeruginosa) as compared to those who were not chronically infected with P. aeruginosa. The
presence of Staphylococcus aureus (S. aureus) on sputum did not affect the IL-17 or IL-23 levels. There was no
correlation between IL-17 or IL-23 levels and FEV1 nor sputum neutrophilia.
Conclusion: The elevated levels of IL-17 and IL-23 might indicate that Th17 cells are implicated in the persistent
neutrophil infiltration in CF lung disease and chronic infection with P. aeruginosa.
Background
The major cause of morbidity and mortality in cystic
fibrosis (CF) is lung damage characterized by bronchiec-
tasis. This damage is the result of the vicious cycle of
chronic infection and inflammation with production of
harmful products such as proteases and oxidants
secreted mainly by neutrophils. A major factor in the
respiratory health of CF subjects is chronic Pseudomo-
nas aeruginosa (P. aeruginosa) infection which is asso-
ciated with a poor clinical outcome [1].
The role of the innate immunity in the pathophysiology
of CF lung inflammation with a dominant neutrophilic
type of inflammation has been established [2]. The role of
the cellular, adaptive immunity however remains unclear
but there is some evidence that lymphocytes might be
involved. Aggregates of T and B lymphocytes were found
beneath the epithelial layer in lung parenchyma of trans-
planted CF patients [3]. Histological analysis of bronchial
biopsies of CF patients with chronic stable disease shows
that lymphocytes are scattered throughout the subepithe-
lium [4]. In healthy individuals, T cells express the cystic
fibrosis transmembrane conductance regulator (CFTR)
and defective CFTR protein affects the cytokine produc-
tion by these T cells [5]. Also, the role of Th1 and Th2
cells and expression of their cytokines has been investi-
gated in cystic fibrosis lung inflammation [6].
Antigen presenting cells such as dendritic cells (DC)
that are activated by bacterial antigens in the bronchial
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pro-inflammatory cytokine. T helper 17 (Th17) cells
produce IL-17A upon binding of IL-23 to its receptor
on the T cell membrane. IL-17A is a pro-inflammatory
cytokine of the IL-17 family that is mainly produced by
Th17 cells [8]. The role of this newly discovered T
helper subset in pulmonary inflammation has been
described in numerous inflammatory diseases such as
asthma [9] and chronic rejection after lung transplanta-
tion [10]. IL-17A induces granulopoiesis via induction of
granulocyte colony-stimulating factor (G-CSF) and neu-
trophil recruitment via induction of chemotactic media-
tors such as IL-8 [11]. IL-22 is another cytokine that, in
addition to IL-17, is produced by the Th17 lineage [12].
Both IL-22 and IL-17A have been shown to be crucial
for maintaining local control of the Gram-negative pul-
monary pathogen, Klebsiella pneumoniae in a mice
model of lung infection [13].
The role of the IL-17A/IL-23 axis and Th17 cells in
cystic fibrosis remains unclear. McAllister et al. [14]
found elevated IL-17A and IL-23 protein levels in
bronchoalveolar lavage (BAL) fluid and sputum of 8 CF
patients during exacerbation. We hypothesized that
IL-17A might be partly responsible for neutrophilic
inflammation in the airways, and that there is chronic
activation of the IL-23/IL-17A axis in CF airways in
“stable” conditions (without exacerbation or intravenous
(IV) antibiotic therapy).
The aims of this study were to quantify both protein
and mRNA levels of IL-17A and mRNA levels of IL-22
and IL-23 in sputum of stable CF patients and to relate
expression of these cytokines in sputum to the chroni-
city of airway infection.
Methods
Study population and study design
Adult (≥16 years) CF patients who did not have an
exacerbation (defined by increase in symptoms, a dete-
rioration of the FEV1 and/or documented radiological
changes) and who were not on IV antibiotic therapy for
at least 8 weeks, were recruited at the adult CF outpati-
ent clinic of the university hospital Gasthuisberg.
Healthy controls were recruited among students and
research fellows of the KULeuven who had no history of
respiratory diseases (no asthma and no symptomatic
allergies). Informed consent was obtained from all sub-
jects and the study was approved by the local ethical
committee.
Clinical characteristics of CF patients were obtained
from the hospital records. Spirometry was performed at
the time of sputum induction and compared to spirometry
results during previous hospital visits. The P. aeruginosa
infection status was determined and patients were categor-
ized as never, free, intermittent or chronic using the Leeds
criteria [15] and specific anti-Pseudomonas IgG antibody
levels as described previously [16].
Patients were considered to be “never infected” when
P. aeruginosa was never cultured from sputum. Patients
were “free from infection” when no P. aeruginosa was
grown from the cultures during the previous 12 months,
but when patients had been positive before this period.
“Intermittent infection” meant that 50% of sputum sam-
ples were positive for P. aeruginosa (with a minimum of
4 samples in different months over one year) and patients
were defined as “chronically infected” when more than
50% of the monthly samples were positive and with
P. aeruginosa IgG antibody levels ≥ 17 AU. A similar
approach was used to categorize S. aureus infection.
Sputum induction
Sputum induction in healthy controls was performed by
inhaling increasing concentrations of hypertonic saline
(3% - 4% - 5%) and using a DeVilbiss nebuliser (Ultra-
Neb 2000 model 200HI) [17]. Each concentration was
inhaled for 7 minutes and subjects were asked to expec-
torate sputum after each inhalation period. Sputum
induction in CF patients was performed with the same
nebuliser, but with the use of a hypertonic saline solu-
tion of 5% NaCl only during 10-20 minutes until
enough sputum was collected. Pre-treatment with a
bronchodilator (salbutamol) was done in both healthy
control subjects and CF patients.
Sputum processing
Sputum samples were processed by selecting mucus plugs
to avoid salivary contamination. Sputum processing was
performed with an adapted protocol from Pizzichini et al.
[18] as previously described [17]. In brief, the selected
sputum plugs were incubated in a volume of 4 times the
weight of the plugs of Hank’s balanced salt solution
(HBSS) (BioWitthaker Europe, Cambrex, Verviers,
Belgium) with 3% bovine serum albumin (BSA) and 0.1%
dithiothreitol (DTT) (Sigma, St. Diego, USA) during
15 minutes on a bench rocker. The cells were washed with
4 times the weight of the plugs with Dulbecco’s phosphate
solution (D-PBS) (BioWitthaker Europe, Cambrex) with
0.5% BSA during 5 minutes on a bench rocker. Samples
were filtrated through a 70 μm Falcon cell strainer (BD
Biosciences, San Jose, California, USA) and centrifuged at
1500 rpm during 10 minutes. The supernatant of each
sample was kept at -20°C for protein analysis. A small part
of the cell pellet was used for cytospins (see further), the
rest was frozen at -80°C with RLT lysis buffer (Qiagen,
Maryland, USA) for further RNA isolation.
Cell counts
Cytospins of sputum cells were made in a Shandon
cytocentrifuge (Techgen, Zellik, Belgium) and stained
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Medion Diagnostics, Düdingen, Switzerland). Per slide,
250 leukocytes and epithelial cells were counted and
percentages of inflammatory cells (macrophages, neutro-
phils, eosinophils and lymphocytes) were calculated on
the total number of leukocytes without considering the
epithelial cells.
Absolute numbers of each cell type were calculated by
multiplying the percentages on cytospins with the total
cell count number counted after isolation.
mRNA measurements in sputum samples
RNA was isolated using the RNeasy mini kit (Qiagen).
cDNA synthesis was performed with Ready-To-Go
You-Prime First-Strand Beads (GE Healthcare Life
Sciences, Uppsala, Sweden). RT-PCR was performed in
an ABI prism 7700 Sequence Detector System (Applied
Biosystems, Foster, USA) for IL-17A, IL-22 and IL-23
with specific Taqman probes and primers, and using
PCR Reaction mix (Invitrogen, Merelbeke, Belgium).
IL-22 primers and probe were developed in the labora-
tory of clinical immunology using Primer Express
(Applied Biosystems) (sequences: forward primer: 5’ ttc
atg ctg gct aag gag gc 3’; reverse primer: 5’ gca gcg ctc act
cat act gac t; Taqman probe: 5’ TAM agc ttg gct gat aac
aac aca gac gtt cgt TAMRA 3’). Primers and probes for
IL-17A and IL-23 were previously published (IL-17A [9];
IL-23 [10]). cDNA plasmids expressing linear amounts of
the target gene, were used as a standard. 18S rRNA was
used as housekeeping gene (Pre-Developed TaqMan®
Assay Reagent Control kit, Applied Biosystems) and all
mRNA values were normalized to 18S rRNA expression
by using ratio of the number of copies of the cytokine
and the housekeeping gene RNA multiplied by 10
4.
Protein measurements in sputum samples
The BD™ CBA Flex Set System and buffer master kit
(BD Biosciences) was used to measure protein levels of
IL-17A in the sputum supernatants. Measurements were
performed as instructed by the manufacturer.
We did previous protein measurements on these sam-
ples including ELISA from different companies and
under different conditions, but we failed to measure
IL-17A. This was probably due to technical reasons,
inherent to the determination of cytokine protein levels
in induced sputum supernatants including the use of
DTT to process the samples and the dilution factor.
Therefore, we could not perform the CBA in all the
samples. We only had a very limited amount of control
samples left so we included new control samples. We
opted to use CBA, since this is a more sensitive techni-
que than ELISA, hence the higher concentrations of
other inflammatory markers (e.g. IL-8) measured in
CBA compared to ELISA in previous studies [19].
Statistical analysis
For the statistical analysis of the results, Graphpad
Prism (Graphad software Inc, San Diego, USA) was
used. For the comparison of two groups, a non-
parametric Mann-Whitney U test was used. Chi-square
test was used to compare categorical variables. Correla-
tions were checked with a non-parametric Spearman test.
Normality was checked with a Kolgomorov-Smirnov test
and variances were tested with F-test. A p-value < 0.05
was considered as significant for all tests.
Results
Study population
Thirty eight stable adult CF patients and 11 healthy
controls were included in the study. Characteristics of
CF patients and control subjects are shown in Table 1.
Twenty-two of the CF patients were using inhaled
antibiotics as maintenance treatment. 21 patients of
the total group were using azithromycin. The never/
free/intermittent group consisted of 17 patients
and the chronic P. aeruginosa group consisted of 21
patients. This second group tended to have a lower
FEV1 although this difference was not statistically
significant (p = 0.096 for FEV1 at time of sputum
induction).
Differential cell counts
Nine out of 11 cytospins from the controls and 34 out
of 38 from the CF patients were of good quality to
allow differential cell counts. Percentages and absolute
numbers of each inflammatory cell type are given in
Table 2. In the CF group we could observe a dominant
neutrophilia compared to the healthy controls.
Cytokine levels in sputum
We measured mRNA levels by RT-PCR in all healthy
controls (n = 11) and CF patients (n = 38). Median
(P25-P75) IL-17A mRNA levels were 0.14 (0.06-0.95) for
controls and 6.1 (2.6-11.6) for CF and median IL-23
mRNA levels 2.4 (0.25-6.2) for controls and 19.3
(8.0-29.2) for CF (p < 0.0001 for both; figure 1A and
1B). IL-22 mRNA levels were negative or very low in
the CF group (data not shown). In the CF group, there
was a strong correlation between IL-17A mRNA and
IL-23 mRNA levels (r = 0.87; p < 0.0001) (Figure 1C). In
healthy controls this correlation was not as strong, but
still significant (r = 0.62; p = 0.043) (data not shown).
We measured IL-17A protein levels with CBA. We
obtained additional sputum supernatant samples in 14
different control subjects (8 female; mean age 27.3) next
to the 3 control samples left from the original group. In
the 16 samples left from the original CF patient group,
we found median IL-17A levels of 18.54 (13.46-22.28)
pg/ml with only 3 samples below the detection limit,
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limit (0.3 pg/ml undiluted). Thus, IL-17A protein levels
in CF patients were significantly higher compared to IL-
17A protein levels in the total group of controls (p <
0.0001; Figure 2).
There was no difference in IL-17A/IL-23 expression
between patients with or without oral azithromycin
therapy, also when we only looked within the group of
chronically infected patients (data not shown). The
group taking inhaled antibiotics tended to have higher
levels of IL-17A mRNA (p = 0.054).
IL-17A and IL-23 expression and infection status and
disease severity
IL-17A mRNA and IL-23 mRNA levels were significantly
higher in the chronic P. aeruginosa group as compared to
the never/free/intermittent group (p = 0.0053 and
p = 0.037 respectively; Figure 3A and 3B).
IL-17A protein levels were available in 16 CF patients
(8 in P. aeruginosa never/free/intermittent group and 8
in chronic group). Median concentration of IL-17A was
19.04 (13.46-22.03) and 18.32 (3.98-23.83) pg/ml in
chronic P. aeruginosa group and in never/free/intermit-
tent group, respectively. These values were not statisti-
cally different.
There was no correlation between IL-17A nor IL-23
levels and the anti-Pseudomonas IgG antibody levels
(data not shown).
There was no difference in IL-17A and IL-23 mRNA
levels between the patients chronically infected with
S. aureus as compared with the never/free/intermittent
g r o u p( p=N S ;F i g u r e3 Ca n d3 D ) .T h ed i f f e r e n c ew a s
also not significant when we excluded the chronic
P. aeruginosa patients (data not shown). There was no
difference in IL-17A protein levels amongst the different
groups of S. aureus infection (data not shown).
Table 1 Characteristics of healthy controls and
CF patients, divided in subgroups according
to P. aeruginosa infection status
CF never/free/intermittent
P. aeruginosa
CF chronic
P. aeruginosa
control subjects
Nr. of subjects 17 21 11
Age (mean ± SD)
in years
26.6 ± 8.0 25.1 ± 4.3 27.5 ± 10.9
Gender (F/M) 11/6 9/12 10/1
BMI (mean ± SD)
in kg/m
2
21.6 ± 3.0 20.2 ± 2.5 NA
Genotype (# of pts dF508del homozygous) 2 16* NA
Exocrine pancreas insufficiency (%) 64.7 100** NA
Current FEV1
(% predicted)
(mean ± SD)
72.8 ± 17 61.9 ± 17.4 Normal values
Mean FEV1
previous year
(% predicted)
(mean ± SD)
73.8 ± 16.6 65.1 ± 16.3 NA
SD: standard deviation, F: female, M: male, NA: not available, pts: patients.
*: p < 0.0001 (Chi-square test), **: p = 0.003 (Chi-square test).
Table 2 Total and differential cell counts
Cell counts (mean ± SD) CF never/free/intermittent
P. aeruginosa
CF chronic P. aeruginosa control subjects
Total cell count (10
6) 3.8 ± 2.9 4.1 ± 4.2 0.7 ± 0.4
% of neutrophils 89.3 ± 11.5 93.3 ± 4.0 41.4 ± 12.4
Absolute numbers of neutrophils (10
6) 3.4 ± 2.8 4.0 ± 3.8 0.32 ± 0.28
% of lymphocytes 0.4 ± 0.6 0.7 ± 1.0 0.8 ± 0.3
Absolute numbers of lymphocytes (10
4) 1.7 ± 2.5 1.8 ± 4.6 1.7 ± 1.6
% of macrophages 9.2 ± 11.2 5.5 ± 3.1 57.3 ± 12.3
Absolute numbers of macrophages (10
5) 3.0 ± 4.1 2.8 ± 4.6 3.8 ± 1.6
% of eosinophils 1.1 ± 2.6 0.5 ± 0.6 0.4 ± 0.05
Absolute numbers of eosinophils (10
4) 3.1 ± 8.3 2.1 ± 4.5 0.15 ± 0.36
Absolute numbers of cells per milliliter and percentages on total leukocytes of sputum cells in healthy controls and patients with CF patients, divided in
subgroups according to P. aeruginosa infection status and healthy controls.
Decraene et al. Respiratory Research 2010, 11:177
http://respiratory-research.com/content/11/1/177
Page 4 of 8There was no correlation between IL-17A protein and
mRNA nor IL-23 mRNA levels and FEV1 % predicted at
time of sputum induction nor with mean FEV1 %o f
previous year nor with sputum neutrophil counts
(expressed either as percentage or absolute number)
(data not shown).
Discussion
In the present study, we found elevated levels of both
IL-17A protein and mRNA levels and also of IL-23
mRNA in sputum of clinically stable CF patients as com-
pared to healthy controls, thus suggesting a potential role
of Th17 cells in the pathophysiology of CF lung disease.
These results were confirmed by significantly increased
IL-17A protein levels and in line with previous data on
IL-17A expression in CF patients during exacerbation.
McAllister et al [14] found elevated IL-17A protein levels
in sputum of adult CF patients during a pulmonary
exacerbation and in these patients, there was a decrease
of the IL-17A protein levels after IV antibiotic therapy.
The same authors found elevated IL-17A protein levels
in BAL fluid of children with CF also during a pulmonary
exacerbation [20]. Our data suggest a chronic activation
of the IL-23/IL-17A axis in CF airways even outside an
episode of pulmonary exacerbation.
Our results indicate that infection with P. aeruginosa
may promote the IL-17A and IL-23 expression in CF,
since we found that patients chronically infected with
P. aeruginosa have higher mRNA expression of both
cytokines than patients who were not chronically
infected. IL-17A protein levels were not different
between P. aeruginosa subgroups but this may be due to
the limited number of sputum samples available for pro-
tein measurement as explained in the methods section.
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Figure 1 IL-17A and IL-23 mRNA levels: CF group compared to
controls. IL-17A (A) and IL-23 (B) mRNA levels in controls (n = 11)
compared to CF group (n = 38). mRNA levels were measured by
RT-PCR. Values were normalized to 18S rRNA (ratio multiplied by
10
4). Comparison of controls and CF group was done by
nonparametric Mann-Whitney U test (p < 0.05 significant). Median
levels are shown by the line. (C): Correlation between IL-17A and
IL-23 mRNA in the CF group (n = 38). Spearman correlation test was
used (p < 0.05 significant) (r = correlation coefficient).
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Figure 2 IL-17A protein levels: CF group compared to controls.
IL-17A protein levels in controls (n = 17) compared to CF group
(n = 16). Protein levels were measured by CBA and multiplied by 9
to correct for dilution into sputum buffers. Open symbols in control
group are original 3 controls and closed symbols are new controls.
Comparison of controls and CF group was done by nonparametric
Mann-Whitney U test (p < 0.05 significant). Median levels are shown
by the line.
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Figure 3 Comparison of IL-17A and IL-23 levels between
patients with different colonisation status of P. aeruginosa and
S. aureus. Comparison of IL-17A and IL-23 mRNA levels between
patients with different colonisation state of P. aeruginosa (A and B)
(never/free/intermittent: n = 17 and chronic: n = 21) and S. aureus
(never/free/intermittent: n = 22 and chronic: n = 16) (C and D)
according to the Leeds criteria. mRNA values were normalized to
18S rRNA (ratio multiplied by 10
4). Comparison between the groups
was done by nonparametric Mann-Whitney U test (p < 0.05
significant). Median levels are shown by the line.
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P. aeruginosa airway infection is able to induce IL-23
release in wild-type C57BL/6 mice while in IL-23
knock-out mice, the airway inflammation caused by
P. aeruginosa was significantly reduced [21]. These data
suggest that the continuous presence of Pseudomonal
antigens in the mucus layer may feature as a strong sti-
mulus for DC activation followed by IL-23/IL-17A
production.
Our results did not show a relation between IL-17A
mRNA and IL-23 mRNA levels and the S. aureus infec-
tion status. In the subgroup of 6 patients infected with
both P. aeruginosa and S. aureus, IL-17A mRNA and
IL-23 mRNA levels were not significantly higher than in
those chronically infected with P. aeruginosa alone. This
is in contrast with findings of Sagel et al., who demon-
strated that the presence of both P. aeruginosa and S.
aureus had an additive effect on concentrations of
inflammatory markers in BAL [22]. Bodini et al. showed
that leukotriene B4 (LTB4) and IL-8 levels in exhaled
breath condensate were also related to the type of bac-
terial infection in CF patients, with highest levels in CF
patients infected by P. aeruginosa [23]. P. aeruginosa
might stimulate the IL-17A/IL-23 axis in the airways via
activation of Toll like receptor (TLR) 4, similar to gram
negative Klebsiella pneumonia [24], while peptidoglycans
and bacterial lipoproteins from Gram-positive bacteria
such as S. aureus mediate their response trough TLR2.
Whether stimulation of P. aeruginosa and S. aureus via
different TLR pathways may result in a different IL-23
expression and different activation of DC and ultimately
in a different disease severity in CF remains speculative.
In our study, CF patients with chronic P. aeruginosa
infection had a trend towards a lower FEV1. Although this
difference was not significant, this trend suggests a more
severe pulmonary disease in CF patients with P. aeruginosa
a n di sc o n s i s t e n tw i t hp r e v i o u sf i n d i n g s[ 1 6 , 2 5 ] .
Our results did not show a significant correlation
between IL-17A or IL-23 mRNA levels and lung func-
tion parameters. We hypothesize that the lack of corre-
lation might be due to the patient selection bias (all of
recruited patients were adults with established lung dis-
ease as evidenced by an already low FEV1). Additional
evaluation in an even larger group of CF patients,
including children with milder lung disease, is war-
ranted. We also observed that in the group of patients
chronically infected with P. aeruginosa,7 6 . 2 %o ft h e
patients were dF508del homozygous as in the other
group this was only 11.8%, confirming previous data
concerning the effect of genotype on lung disease sever-
ity and pulmonary infection status [26].
T h es l i g h t l yh i g h e re x p r e s s i o no fI L - 1 7 Am R N A
expression in patients taking inhaled antibiotics could
be explained by the fact that inhaled antibiotics
are mostly taken by patients chronically infected with
P. aeruginosa.
Patients taking AZI had similar levels of IL-17A and
IL-23. We could not observe an effect of AZI on inflam-
matory cytokine expression in this cross-sectional study.
Longitudinal controlled studies are required to study the
effect of AZI on production of inflammatory cytokines.
The presence of IL-17A in sputum of CF patients out-
side a CF exacerbation indicates that IL-17A might be
involved in the persistent neutrophilia present in the air-
ways of CF patients. We did not find a correlation
between IL-17A nor IL-23 sputum levels and sputum
neutrophilia in stable CF patients. We acknowledge that
measuring myeloperoxidase (MPO) or neutrophil elas-
tase (NSE) might be a good alternative for the less reli-
able neutrophil sputum counts [27]. We found a
significant reverse correlation between NSE and FEV1
(data not shown). It is yet to be investigated whether
MPO or NSE are better markers for neutrophil inflam-
mation to use in the clinical setting. NSE did however
not correlate with IL-17A or IL-23 levels (data not
shown). This suggests that other, IL-17-independent,
pathways are also implicated in the neutrophil recruit-
ment to the site of inflammation. C5a, LTB4 and plate-
let-activating factor (PAF) have been characterized as
important neutrophil-stimulating mediators in CF air-
ways [28]. Additional studi e si na na n i m a lm o d e lw i l l
help us to determine whether blocking of IL-17A is able
to reduce neutrophilic inflammation in CF airways.
IL-22 mRNA levels were very low or negative in our
samples. This is in agreement with Aujla et al. [13], who
found similarly low levels of IL-22 in BAL samples of
CF patients during exacerbation, as opposed to high
BAL levels for IL-17A and IL-23. As we have only
recruited CF patients outside of an exacerbation, it
seems logic that sputum IL-22 expression in these clini-
cally stable patients would be even lower as observed in
the study of Aujla et al. The observation that IL-22
was increased in lung tissue and lung lymphocytes of
P. aeruginosa-infected patients with CF might suggest
that IL-22 acts locally in the lung tissue, but is not pro-
duced into the airway lumen, in contrast to IL-17A.
Accidently, in our control group, only one male
subject was present. Although theoretically it is always
possible that gender difference might influence our
results in the control population, we believe this will not
bias our results. We indeed do not expect differences in
cytokine mRNA expression depending on the gender in
the control group since we also did not detect different
levels of cytokines depending on the gender in the CF
group.
As already mentioned, Th17 lymphocytes are
considered to be the main source of IL-17A. However,
lymphocyte percentages were very low in sputum of our
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the sole source of the expression of IL-17A in our sam-
ples. Other lymphocytes, like NKT cells [29] and
gδ T cells [30] can also produce IL-17A. These lympho-
cytes however are even less abundant than CD4+ T cells
and are unlikely to be the source of IL-17A found in the
sputum samples of our patients. Immunostaining experi-
ments showed that eosinophils express IL-17A mRNA
in asthmatic patients [31]. In mice IL-17A mRNA
expression was found in neutrophils [32] and macro-
phages [33]. The cellular source of the increased IL-17A
in our CF patients remains to be elucidated. The cellular
source of IL-23 in sputum is probably lung macrophages
and dendritic cells.
Conclusions
Our study is the first to show the presence of IL-17A
protein and mRNA and IL-23 mRNA in sputum of a
group of stable CF patients. These results suggest a
potential role for the IL-23/IL-17A axis in CF lung
inflammation and confirm that the adaptive immune
system is involved in the pathophysiology of CF lung
disease. Chronic infection with P. aeruginosa appears to
be associated with higher mRNA expression of these
cytokines in CF airways and additional longitudinal stu-
dies are needed to support the importance of IL-23/
IL-17A mediated airway inflammation in the develop-
ment of CF lung disease. This should allow us to deter-
mine the potential therapeutic value of blocking IL-17
in CF lung disease.
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